(ATDN) Interleukin-2 for HIV

(ATDN) Interleukin-2 for HIV

Treatment Review #17 - March 1995

A trial studying IL-2 by subcutaneous injection for the treatment of HIV infection is enrolling in New York and other cities. Because of the side effects of IV infusion, some doctors are giving the drug by subcutaneous injection. This trial will study the combination of IL-2 and AZT. Participants will be divided into two groups. Everyone will take AZT. The first group will also be given shots of IL-2. After 24 weeks, the second group will be given shots of IL-2 and the first group will take only AZT. To participate in this study you must be HIV+, 18 years or older, and have a T4 cell count between 300 and 700. You must have taken and tolerated AZT for 6 months or longer at 500 mg./day. You cannot have any opportunistic illnesses or be pregnant or nursing. Call The Network for more information.

950301
ATR01715

Always watch for outdated information. This article first appeard in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1995 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1995. AEGIS.